Orthofix International NV (NASDAQ:OFIX) shares were down 11.1% during mid-day trading on Tuesday . The company traded as low as $42.02 and last traded at $42.23, with a volume of 263,377 shares changing hands. The stock had previously closed at $47.52.

A number of research analysts have recently issued reports on OFIX shares. TheStreet upgraded shares of Orthofix International NV from a “hold” rating to a “buy” rating in a research note on Monday, May 2nd. Zacks Investment Research cut shares of Orthofix International NV from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 4th.

The stock’s 50-day moving average price is $45.36 and its 200-day moving average price is $42.38. The stock’s market capitalization is $771.00 million.

Orthofix International NV (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 1st. The medical device company reported $0.41 EPS for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.08. The company earned $104.10 million during the quarter, compared to analyst estimates of $102.40 million. During the same quarter last year, the company posted $0.36 EPS. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts forecast that Orthofix International NV will post $1.36 EPS for the current fiscal year.

In related news, Director Maria Sainz sold 4,157 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $46.33, for a total value of $192,593.81. Following the transaction, the director now owns 20,828 shares in the company, valued at approximately $964,961.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Robert Allen Goodwin II sold 13,187 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $44.00, for a total transaction of $580,228.00. Following the completion of the transaction, the insider now owns 39,607 shares in the company, valued at approximately $1,742,708. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently made changes to their positions in the stock. California State Teachers Retirement System raised its position in shares of Orthofix International NV by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 34,774 shares of the medical device company’s stock worth $1,363,000 after buying an additional 600 shares during the period. GSA Capital Partners LLP raised its position in shares of Orthofix International NV by 18.3% in the fourth quarter. GSA Capital Partners LLP now owns 42,609 shares of the medical device company’s stock worth $1,671,000 after buying an additional 6,601 shares during the period. Russell Frank Co raised its position in shares of Orthofix International NV by 80.3% in the fourth quarter. Russell Frank Co now owns 43,978 shares of the medical device company’s stock worth $1,741,000 after buying an additional 19,582 shares during the period. Marshall Wace LLP bought a new position in shares of Orthofix International NV during the fourth quarter worth approximately $1,443,000. Finally, Diamond Hill Capital Management Inc. raised its position in shares of Orthofix International NV by 5.6% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 861,860 shares of the medical device company’s stock worth $33,794,000 after buying an additional 45,984 shares during the period.

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.